300026 Tianjin Chase Sun Pharmaceutical
- 3.58
- -0.04-1.10%
Tianjin Chase Sun Pharmaceutical News
Red Sun Pharmaceutical (300026.SZ) plans to pay 0.3 yuan for every 10 shares in 2023, excluding interest on May 23
Hongri Pharmaceutical (300026.SZ) announced that the company plans to pay 0.30 for every 10 shares to all shareholders in 2023...
Express News | Hongri Pharmaceutical: Obtained Valsartan Amlodipine Tablets (I) Drug Registration Certificate
Joint Credit: Follow the changes in the chairman and general manager of Hongri Pharmaceutical
Joint Financial Credit is concerned that according to the “Notice Concerning the Resignation of the Chairman of the Company and By-election of the Director, Chairman, Vice Chairman, and Adjustment of Special Committee Members and the Appointment of the Company's Senior Management” disclosed by Hongri Pharmaceutical on April 2, 2024, and the “Notice Concerning the Retirement and Resignation of the Company's Vice Chairman, Director and General Manager” disclosed on March 12, 2024, Mr. Yao Xiaoqing applied to resign as the company's legal representative, chairman, director and relevant positions in the special committee of the board of directors after resigning; former vice chairman, Ms. Zheng Dan, director and general manager, is
Red Sun Pharmaceutical (300026.SZ): Yao Xiaoqing resigns as chairman
Gelonghui, April 1, 丨 Hongri Pharmaceutical (300026.SZ) announced that the board of directors of the company recently received a written application for resignation from Mr. Yao Xiaoqing, the chairman of the company. Mr. Yao Xiaoqing applied to resign as the company's legal representative, chairman, director and relevant positions in the special committee of the board of directors due to personal work reasons. After his resignation, he no longer held any position in the company.
Hongri Pharmaceutical (300026.SZ): The subsidiary looks forward to the pharmaceutical industry selling esprolol hydrochloride raw materials
Gelonghui, March 29丨An investor asked Hongri Pharmaceutical (300026.SZ) on the investor interactive platform. “Do your company and subsidiaries have esprolol hydrochloride APIs and corresponding formulations?” The company replied that the company's subsidiary expects the pharmaceutical industry to sell esprolol hydrochloride APIs.
Hongri Pharmaceutical (300026.SZ): Ketorolac tromethanol injection is currently under CDE review
Gelonghui, March 29丨An investor asked Hongri Pharmaceutical (300026.SZ) on the investor interactive platform, “The consistency evaluation of your company's ketorolac tromethotriol injection completed various technical reviews at the end of August 2023. Why hasn't it been approved until now?” The company replied that ketorolac and tromethotriol injections are currently under CDE review.
Red Sun Pharmaceutical (300026.SZ): Net profit for 2023 will drop 18.84% to 507 million yuan, and plans to distribute 10 to 0.3 yuan
Gelonghui March 28 | Hongri Pharmaceutical (300026.SZ) released its 2023 annual report. In 2023, the company achieved operating income of 6.109 billion yuan, a year-on-year decrease of 8.14%; net profit attributable to shareholders of listed companies was 507 million yuan. , a year-on-year decrease of 18.84%; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 376 million yuan, a year-on-year decrease of 34.20%; basic earnings per share were 0.17 yuan; it is proposed to distribute a cash dividend of 0.30 yuan (tax included) for every 10 shares to all shareholders.
Express News | The industry is facing “pain” due to the decline in revenue from many companies in traditional Chinese medicine formula pellets
Hongri Pharmaceutical (300026.SZ): Chase Group's shareholding ratio fell below 5%
Gelonghui, March 19 | Hongri Pharmaceutical (300026.SZ) announced that the company recently received the “Simplified Equity Change Report” issued by Chase Group. I learned that Chase Group reduced its holdings (including passive holdings reduction and judicial auctions) of the company's shares in total 143,171,029 shares (including passive holdings reduction and judicial auctions) from July 9, 2020 to the date of disclosure of the report from July 9, 2020 to the date of disclosure of the report, accounting for 4.76577% of the company's total share capital. After this change in equity, the shares of the company held by Chase Group fell from 293,376,722 shares to 150,20
Zheng Dan, vice chairman, director and general manager of Hongri Pharmaceutical (300026.SZ) retires
Hongri Pharmaceutical (300026.SZ) announced that the board of directors of the company recently received Zheng Dan from the vice chairman, director and general manager...
Hongri Pharmaceutical (300026.SZ) Performance Report: Net profit of 529 million yuan in 2023 fell 15.22% year on year
Gelonghui, Feb. 29 | Hongri Pharmaceutical (300026.SZ) announced its 2023 annual results report. In 2023, the company's total revenue was 6.127 billion yuan, down 7.86% from the same period last year; total profit of 629 million yuan, down 12.19% year on year; net profit attributable to shareholders of listed companies was 529 million yuan, down 15.22% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 398 million yuan; basic earnings per share were 0.18 yuan.
Chase Group, the majority shareholder of Hongri Pharmaceuticals (300026.SZ), reduced its holdings by 30.22 million shares
Hongri Pharmaceutical (300026.SZ) announced that Tianjin Datong Investment Group Co., Ltd., the shareholder of the company holds more than 5% of the shares (...
Hongri Pharmaceutical (300026.SZ) issued a pre-reduction. Net profit is expected to be 502 million yuan to 538 million yuan in 2023, a year-on-year decrease of 13.82% to 19.58%
Hongri Pharmaceutical (300026.SZ) disclosed its 2023 annual results forecast. The company is expected to belong to listed company shares...
Chase Group, a shareholder of Hongri Pharmaceutical (300026.SZ), passively reduced its holdings of the company by 1.12%
Hongri Pharmaceutical (300026.SZ) issued an announcement. As of the date of disclosure of the announcement, the company's shareholder Chase Group passively reduced its shareholding...
Express News | Twenty listed companies, including Hengrui Pharmaceutical and China Resources Shuanghe, announced after the market that drugs entered the national health insurance catalogue, Junshi Biotech and Zhongsheng Pharmaceutical's COVID-19 drugs were included
Red Day Pharmaceutical (300026.SZ): Xuebijing injection continues to be included in the national medical insurance drug catalogue
Gelonghui December 13丨Hongri Pharmaceutical (300026.SZ) announced that according to the results of the 2023 contract renewal negotiations for the “National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalogue (2023)” announced by the National Health Insurance Administration and the Ministry of Human Resources and Social Security on December 13, 2023, the blood purification injection produced by Tianjin Hongri Pharmaceutical Co., Ltd. was renewed according to current conditions and continued to be included in category B of the “National Medical Insurance Drug Catalogue”.
Red Day Pharmaceutical (300026.SZ): Chaosi electronic product wrist oximeter obtained 510 (k) certification from the US FDA
Glonghui December 13丨Hongri Pharmaceutical (300026.SZ) announced that recently, Beijing Chaosi Electronic Technology Co., Ltd. (“Chaosi Electronics”), a wholly-owned subsidiary of Tianjin Hongri Pharmaceutical Co., Ltd., received a notice from the U.S. Food and Drug Administration (US Food and Drug Administration, hereinafter referred to as “FDA”), and Chaosi Electronics has obtained 510 (k) certification from the US FDA.
Hongri Pharmaceutical (300026.SZ): The medical device and raw materials business has overseas sales
Gelonghui November 14: Some investors asked Hongri Pharmaceutical (300026.SZ) on the investor interactive platform, “Does your company have overseas business?” The company replied that the company's medical devices and raw materials business were sold overseas.
Chase Group, the majority shareholder of Hongri Pharmaceutical (300026.SZ), reduced its holdings by a total of 46.012,300 shares
According to the Zhitong Finance App, Red Day Pharmaceutical (300026.SZ) announced that from September 23, 2020 to November 2, 2023, Tianjin Chase Investment Group Co., Ltd. (“Chase Group”), which holds more than 5% of the company's shares, reduced its holdings of the company's shares by a total of 46.012,300 shares through major transactions, centralized bidding transactions, and execution of court decisions, accounting for 1.5316% of the company's total share capital.
Tianjin Chase Sun Pharma's Muscle Relaxant Passes Drug Consistency Test
Tianjin Chase Sun Pharmaceutical (SHE:300026) said its rocuronium bromide injection used as a muscle relaxant during muscle surgery recently passed a drug consistency evaluation. Rocuronium bromide is
Analysis
Price Target
No Data
